Apellis Pharmaceuticals Inc (NAS:APLS)
$ 39.68 -3.92 (-8.99%) Market Cap: 4.82 Bil Enterprise Value: 5.07 Bil PE Ratio: 0 PB Ratio: 18.04 GF Score: 38/100

Apellis Pharmaceuticals Inc at Citi BioPharma Conference Transcript

Sep 07, 2022 / 05:00PM GMT
Release Date Price: $64.25 (+10.76%)
Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

Welcome, everyone. Thanks for joining. I'm Yigal Nochomovitz, I'm one of the biotech analysts here at Citi. And it's my great pleasure to have with me the senior management from Apellis Pharma, Cedric Francois, CEO and Co-Founder; Adam Townsend, Chief Commercial Officer; Tim Sullivan, Chief Financial Officer.

So welcome all of you. Cedric, it's been a long road since we first met back in Louisville, I think in the summer of 2015 when you were still private. A lot has happened since then in terms of clinical progress, expansion of the pipeline. So tell us how do you see -- how is the mission of Apellis evolved? How would you grade yourself against the objectives that you set out for yourself back in the early days 7 years ago.

Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director

Well, I'll let others grade us. But it's been a fantastic ride, of course, right? I mean when we started Apellis about a decade ago, we set out initially on a mission to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot